**Exhibit 12.01**

 

CERTIFICATION

 

I, Michael B. Ohanessian certify that:

 

1.             I have reviewed this annual report on Form 20-F of GeneticTechnologies Limited;

 

2.             Basedon my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade and, in light of the circumstances under which such statements were made,is not misleading with respect to the period covered by this report;

 

3.             Basedon my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the Company as of, and for,the periods presented in this report;

 

4.             TheCompany’s other certifying officers and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the Company and have:

 

(a)           Designedsuch disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the company, including its consolidated subsidiaries,is made known to us by others within those entities, particularly during theperiod in which this report is being prepared;

 

(b)           Evaluatedthe effectiveness of the Company’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and

 

(c)           Disclosedin this report any change in the Company’s internal control over financialreporting that occurred during the period covered by the annual report that hasmaterially affected, or is reasonably likely to materially affect the Company’sinternal control over financial reporting; and

 

5.             TheCompany’s other certifying officer(s) and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theCompany’s auditors and the audit committee of the Company’s Board of Directors(or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely toadversely affect the Company’s ability to record, process, summarize and reportfinancial information; and

 

(b) Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the Company’s internal control over financialreporting.

 
| Date: December 18, 2007 |                       |
|------------------------------|----------------------------|
|                         |                       |
|                         | /s/  Michael B. Ohanessian |   |
|                         | **Michael B. Ohanessian**  |

 

A signed original of this written statementrequired by Section 302 has been provided to Genetic Technologies Limitedand will be retained by Genetic Technologies Limited and furnished to theSecurities and Exchange Commission or its staff upon request.

 

----